Tiny amounts of lithium — a natural metal — may help protect the brain from Alzheimer’s and signs of aging, new research shows. Scientists at Harvard Medical School and Rush University found that when mice were fed a low-lithium diet, their brains developed more inflammation and signs of aging accelerated. The findings were published Wednesday in the journal Nature. Turns out, lithium may play a critical role in how the brain stays healthy, the researchers found. In the study, they compared normal mice to mice bred to develop brain changes linked to Alzheimer’s, including a build-up of sticky proteins.  Mice on low-lithium diets developed problems more quickly, while those given a specific lithium compound called lithium orotate saw signs of brain improvement. When given lithium orotate, mice had fewer memory problems and fewer of the sticky clumps known as beta amyloid plaques. In people, those plaques are hallmarks of Alzheimer’s. Many people know lithium as a drug used to treat bipolar disorder and depression. It’s been used for decades. But this study suggests that very small amounts of lithium are naturally present in the body, and it may be essential for brain health. Researchers suspect that beta amyloid binds to lithium and prevents it from reaching brain cells that need it.  Without enough lithium, cells called microglia, which help clean up waste in the brain,…  read on >  read on >

A new weight loss pill made by Eli Lilly helped people lose a significant amount of weight in a recent study. Taken at the highest dose, orforglipron helped patients lose an average 27.3 pounds, or 12.4% of their body weight, over 72 weeks. Eli Lilly says it plans to apply for U.S. Food and Drug Administration (FDA) approval by the end of the year to market the drug. If approved, the pill could become a simpler alternative to injectable medications like Wegovy, Ozempic, Zepbound and Mounjaro, which are used to treat obesity and type 2 diabetes. Pills are easier to make and “can be manufactured at a significant scale,” Kenneth Custer, Eli Lilly’s president of cardiometabolic health, told The New York Times. “There are orders of magnitude differences in how many we can support,” he said, adding that pills could also help people in countries without access to cold storage needed for injected drugs. Like the injected medications, the new pill belongs to the GLP-1 class of drugs. GLP-1 drugs work by helping people feel full longer and by slowing digestion, according to the Cleveland Clinic. The recent study included 3,127 adults who were randomly assigned to take orforglipron or a placebo. Three different dosages of the drug were evaluated. In addition to weight loss, people taking the drug also saw improvements in cholesterol, triglyceride…  read on >  read on >

A new weight loss pill made by Eli Lilly helped people lose a significant amount of weight in a recent study. Taken at the highest dose, orforglipron helped patients lose an average 27.3 pounds, or 12.4% of their body weight, over 72 weeks. Eli Lilly says it plans to apply for U.S. Food and Drug Administration (FDA) approval by the end of the year to market the drug. If approved, the pill could become a simpler alternative to injectable medications like Wegovy, Ozempic, Zepbound and Mounjaro, which are used to treat obesity and type 2 diabetes. Pills are easier to make and “can be manufactured at a significant scale,” Kenneth Custer, Eli Lilly’s president of cardiometabolic health, told The New York Times. “There are orders of magnitude differences in how many we can support,” he said, adding that pills could also help people in countries without access to cold storage needed for injected drugs. Like the injected medications, the new pill belongs to the GLP-1 class of drugs. GLP-1 drugs work by helping people feel full longer and by slowing digestion, according to the Cleveland Clinic. The recent study included 3,127 adults who were randomly assigned to take orforglipron or a placebo. Three different dosages of the drug were evaluated. In addition to weight loss, people taking the drug also saw improvements in cholesterol, triglyceride…  read on >  read on >

More than 1 in 10 Americans have used a GLP-1 drug for weight loss, a new survey by the RAND research group reveals. About 12% say they’ve tried GLP-1 drugs, like Ozempic, Wegovy or Zepbound, with rates of use highest among people ages 50 to 64, survey results show. “Of all demographic groups, women between the ages of 50 and 64 had the highest use rate,” wrote the research team led by Robert Bozick, director of RAND Survey Panels. “One in five women, or 20%, reported having ever used GLP-1 agonists.” Further, many GLP-1 users report side effects like nausea and diarrhea, the survey found. The report is the most recent and largest survey to date estimating how many Americans have used the revolutionary weight-loss drugs, researchers said. Glucagon-like peptide-1 (GLP-1) drugs mimic the GLP-1 hormone, which helps control insulin and blood sugar levels, decreases appetite and slows digestion of food. Since 2020, prescriptions for GLP-1 drugs have more than tripled, researchers said in background notes. To see how widespread use has become, RAND surveyed 8,793 Americans in April and May. Along with the 12% who have tried the drugs, another 14% are interested in giving them a go, the survey found. Meanwhile, three-quarters of Americans (74%) say they don’t plan to try GLP-1 drugs. Respondents said the most common side effects associated with GLP-1…  read on >  read on >

More than 1 in 10 Americans have used a GLP-1 drug for weight loss, a new survey by the RAND research group reveals. About 12% say they’ve tried GLP-1 drugs, like Ozempic, Wegovy or Zepbound, with rates of use highest among people ages 50 to 64, survey results show. “Of all demographic groups, women between the ages of 50 and 64 had the highest use rate,” wrote the research team led by Robert Bozick, director of RAND Survey Panels. “One in five women, or 20%, reported having ever used GLP-1 agonists.” Further, many GLP-1 users report side effects like nausea and diarrhea, the survey found. The report is the most recent and largest survey to date estimating how many Americans have used the revolutionary weight-loss drugs, researchers said. Glucagon-like peptide-1 (GLP-1) drugs mimic the GLP-1 hormone, which helps control insulin and blood sugar levels, decreases appetite and slows digestion of food. Since 2020, prescriptions for GLP-1 drugs have more than tripled, researchers said in background notes. To see how widespread use has become, RAND surveyed 8,793 Americans in April and May. Along with the 12% who have tried the drugs, another 14% are interested in giving them a go, the survey found. Meanwhile, three-quarters of Americans (74%) say they don’t plan to try GLP-1 drugs. Respondents said the most common side effects associated with GLP-1…  read on >  read on >

Long after floodwaters recede, the impact of flooding on the health of older adults is profound, new research shows.  Rates of hospitalizations for a range of conditions affecting the skin and nervous system, as well as poisonings, injuries or mental health woes were all elevated during and after major floods, according to a new data analysis. There’s much that can be done to prevent many of these hospitalizations, however. “Targeted outreach and robust evacuation planning for vulnerable populations, such as older individuals, along with community-based alert systems, are crucial to minimizing health impacts,” said a group led by Sarika Aggarwal. She’s a PhD candidate at the Harvard T.H. Chan School of Public Health. The team published its findings July 30 in The Lancet Planetary Health. The study looked at Medicare hospitalization data from 2000 to 2016, then compared it to information from the Global Flood Database on flooding in the U.S. The study focused on hospitalizations for patients aged 65 or older, covering 13 disease conditions. The hospitalizations all occurred within four weeks of a flooding event.  More than 4.5 million hospitalizations linked to 72 “significant flood events” were part of the analysis. Aggarwal’s team observed elevated rates of hospitalizations for seniors from a number of causes: A 3.1% rise in admissions for skin diseases A 2.5% rise in admissions for nervous system disorders A 1.1%…  read on >  read on >

Long after floodwaters recede, the impact of flooding on the health of older adults is profound, new research shows.  Rates of hospitalizations for a range of conditions affecting the skin and nervous system, as well as poisonings, injuries or mental health woes were all elevated during and after major floods, according to a new data analysis. There’s much that can be done to prevent many of these hospitalizations, however. “Targeted outreach and robust evacuation planning for vulnerable populations, such as older individuals, along with community-based alert systems, are crucial to minimizing health impacts,” said a group led by Sarika Aggarwal. She’s a PhD candidate at the Harvard T.H. Chan School of Public Health. The team published its findings July 30 in The Lancet Planetary Health. The study looked at Medicare hospitalization data from 2000 to 2016, then compared it to information from the Global Flood Database on flooding in the U.S. The study focused on hospitalizations for patients aged 65 or older, covering 13 disease conditions. The hospitalizations all occurred within four weeks of a flooding event.  More than 4.5 million hospitalizations linked to 72 “significant flood events” were part of the analysis. Aggarwal’s team observed elevated rates of hospitalizations for seniors from a number of causes: A 3.1% rise in admissions for skin diseases A 2.5% rise in admissions for nervous system disorders A 1.1%…  read on >  read on >

Dallas Cowboys guard Rob Jones will miss about two to three months after breaking a bone in his neck during the team’s first padded practice of training camp, a new report from the team shows. Jones, 26, told the team’s website Monday that he got hurt early in Sunday’s practice in California but was still able to finish the session. The injury is a tough break for the four-year veteran, who had been working with the starters on the offensive line. Jones signed a one-year, $3.75 million contract with Dallas in the offseason to add depth at guard, NBC News said. “It happened right at the first,” Jones told the team’s website. His absence could clear the way for rookie first-round pick Tyler Booker to start. Coaches were already impressed with Booker, and he was expected to compete for a starting job even before the injury, the team said. Jones began his NFL career with the Miami Dolphins as an undrafted free agent. He started all 17 games last season and has 30 career starts over four years. The Cowboys still have other experienced players who can step in. Saahdiq Charles, who spent four seasons in Washington, joined the team this offseason.  Brock Hoffman also has starting experience. He filled in for Zack Martin last season. Martin retired earlier this year. More information UVA Health…  read on >  read on >

Dallas Cowboys guard Rob Jones will miss about two to three months after breaking a bone in his neck during the team’s first padded practice of training camp, a new report from the team shows. Jones, 26, told the team’s website Monday that he got hurt early in Sunday’s practice in California but was still able to finish the session. The injury is a tough break for the four-year veteran, who had been working with the starters on the offensive line. Jones signed a one-year, $3.75 million contract with Dallas in the offseason to add depth at guard, NBC News said. “It happened right at the first,” Jones told the team’s website. His absence could clear the way for rookie first-round pick Tyler Booker to start. Coaches were already impressed with Booker, and he was expected to compete for a starting job even before the injury, the team said. Jones began his NFL career with the Miami Dolphins as an undrafted free agent. He started all 17 games last season and has 30 career starts over four years. The Cowboys still have other experienced players who can step in. Saahdiq Charles, who spent four seasons in Washington, joined the team this offseason.  Brock Hoffman also has starting experience. He filled in for Zack Martin last season. Martin retired earlier this year. More information UVA Health…  read on >  read on >